Your session is about to expire
← Back to Search
Norepinephrine-Dopamine Reuptake Inhibitor
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
Phase 2
Waitlist Available
Led By Jed E Rose, Ph.D.
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-7 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing centanafadine, a medication taken regularly, to help adult smokers quit. The study aims to see if this medication can reduce cravings or make quitting easier.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4-7 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-7 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Smoking Abstinence CO Reading
Smoking Abstinence Self Reported
Secondary study objectives
REDUCTION IN INCIDENCE OF NAUSEA
Side effects data
From 2019 Phase 2 trial • 13 Patients • NCT0408136314%
Vessel Puncture Site Bruise
100%
80%
60%
40%
20%
0%
Study treatment Arm
Swallowed Capsules Cohort
Sprinkled Onto Applesauce Cohort
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CentanafadineExperimental Treatment1 Intervention
Participants will receive centanafadine sustained release (SR) tablets, orally at a TDD of 400 milligrams (mg), administered as 200 mg doses, BID, approximately 4 to 6 hours apart, for a total of 7 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Centanafadine
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
265 Previous Clinical Trials
169,048 Total Patients Enrolled
Jed E Rose, Ph.D.Principal InvestigatorRose Research Center
12 Previous Clinical Trials
2,633 Total Patients Enrolled